Adalimumab alone and in combination with disease‐modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
AUTOR(ES)
Burmester, Gerd R
FONTE
BMJ Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1954645Documentos Relacionados
- Evidence for early disease-modifying drugs in rheumatoid arthritis
- Step‐up combination versus switching of non‐biological disease‐modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
- Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
- Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.
- Glucosamine: A potential disease-modifying agent in osteoarthritis?